Skip to main content
Loading

Innovations in AAV Design and Emerging Alternatives for Gene Delivery

18 Sep 2025
Next Gen Vector Engineering & Delivery
  • Engineering capsids with enhanced tissue specificity, immune evasion, and payload capacity.
  • Exploring the potential of antibody-oligonucleotide conjugates (AOCs), peptides, and lipid nanoparticles (LNPs) for efficient and targeted delivery.
  • Evaluating delivery platforms across indications to optimize safety, durability, and clinical translation.
Industry Expert
Robert Lin, Chief Executive Officer - Avista Therapeutics